Contingency Management for Opioid and Stimulant Use Disorders in Primary Care
NCT ID: NCT05288751
Last Updated: 2025-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
56 participants
INTERVENTIONAL
2022-06-15
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Contingency Management to Enhance Office-Based Buprenorphine Treatment
NCT04024059
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
NCT04927143
Contingency Management for Stimulant Use Disorders
NCT05097547
Incentives to Decrease Opioid Use - Pilot
NCT04235582
Implementing Contingency Management for Stimulant Use in Specialty Addiction Treatment Organizations
NCT05702021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment as usual (TAU)
These patients will not be assigned to the CM programs, but will be invited to complete study measures at the same time points: baseline, 3-months, 6-months, and 12-months.
No interventions assigned to this group
Attendance-only CM
Patients in this arm complete an appointments with his or her primary care provider (PCP) or member of the PCP's microteam . These appointments must be initiated by the PCP/microteam in accordance with the patient's treatment plan for regular follow-up appointments.
Contingency Management
Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
Attendance + abstinence CM
Patients who test stimulant-positive during the initial urine drug screen (UDS) at their intake visit will be invited to additionally enroll in the abstinence CM schedule. All of the attendance-only CM rules described previously will apply to patients in the attendance + abstinence program.
Contingency Management
Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Contingency Management
Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Opioid Use Disorder and/or Stimulant Use Disorder
* Recently initiated medications for opioid use disorder (MOUDs) at Broadway Family Medicine (BFM), within 2 weeks of recruitment
* Have an active prescription for buprenorphine-naloxone (Suboxone)
Exclusion Criteria
* Dementia, development disabilities, or cognitive functioning that is too low to participate in study measures, as determined by chart review and consultation with overseeing physician.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Levy, MD
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMCH-2022-30581
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.